Peptide and antibody imaging in lung cancer

Seminars in Nuclear Medicine

Volumn 32, Issue 4, 2002, Pages 276-292

  Machac, Josef ^a,b   Krynyckyi, Borys ^a,b   Kim, Chun ^a,b  

^a MOUNT SINAI HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 FLUOROPROPIONYL 1 DEXTRO PHENYLALANINE) OCTREOTIDE F 18; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCREOTIDE[3 TYROSINE] IN 111; ANGIOPEPTIN; BOMBESIN RECEPTOR; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CHOLECYSTOKININ RECEPTOR; DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; GASTRIN RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; INDIUM 111; IODINE 123; IODINE 131; MONOCLONAL ANTIBODY; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TECHNETIUM 99M NOFETUMOMAB MERPENTAN; TECHNETIUM 99M NR LU 10; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE I 125; VERLUMA;

ARTICLE; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FEVER; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RASH; URTICARIA;

EID: 0036808917     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.126053     Document Type: Article

References (102)

1. Stoller JK, Ahmad M, Rice TW: Solitary pulmonary nodules. Cleve Clin J Med 55:68-71, 1988
2. Templeton A, Jansen C, Lehr J, et al: Solitary pulmonary lesions: Computer aided differential diagnosis and evaluation of mathematical methods. Radiology 89:605-613, 1967
3. Edwards F, Schaefer P, Callahan S, et al: Bayesian statistical theory in the preoperative diagnosis of pulmonary lesions. Chest 92:888-891, 1987
4. Libshitz HI, McKenna RJ Jr: Mediastinal lymph node size and lung cancer. AJR Am J Roentgenol 143:715-718, 1984
5. Breitz HB, Sullivan K, Nelp WB: Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med 23:127-132, 1993
6. Gould MK, MacLean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA 285:914-924, 2001
7. Higashi K, Seki H, Taniguchi M, et al. Bronchoalveolar carcinoma: False-negative results on FDG-PET. J Nucl Med 38:79P, 1997
8. Duhaylongsod FD, Lowe VJ, Fujiwara T, et al: Differential diagnosis of lung tumor with positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110:130-139, 1995
9. Gupta NC, Maloof J, Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943-948, 1996
10. Adams S, Baum RP, Hertel A, et al: Metabolic (PET) and receptor (SPECT) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19:641-647, 1998
11. Pasquali C, Rubello D, Sperti C, et al: Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22:588-592, 1998
12. Sugawara Y, Braun DK, Kison PV, et al: Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results. Eur J Nucl Med 25:1238-1243, 1998
13. 125I-HAS. Eur J Nucl Med 26:333-341, 1999
14. Shreve P, Steventon S, Deers E, et al: Oncologic diagnosis with 2[fluorine-18] fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 207:431-437, 1998
15. Serafini AN: From monoclonal antibodies to peptides and molecular recognition units: An overview. J Nucl Med 34:533-536, 1993
16. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
17. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814-819, 1990 (suppl)
18. Wahl RL, Parker CW, Philpott GW: Improved radioimaging and tumor localization with monoclonal F(ab′)2. J Nucl Med 24:316-325, 1983
19. Hertel A, Baum RP, Auerbach B, et al: Klinische relevanz humaner anti-maus antikoerper (HAMA) in der immunszintigraphie. Nucklearmedizin 29:221-227, 1990
20. Moffat FD Jr, Pinsky CM, Hammershaimb L, et al: Clinical utility of external immunoscintigraphy with the IMMUN-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 14:2295-2305, 1996
21. Keenan AM, Hurbert JC, Larson SM: Monoclonal antibodies in nuclear medicine. J Nucl Med 26:531-537, 1985
22. Package insert. Dr. Karl Thomae GmbH, Boehringer Ingelheim International GmbH, DuPont Radiopharmaceutical Division, Ingelheim, Germany
23. Hornick JL, Sharifi J, Khawli LA, et al: Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med 41:355-362, 2000
24. Hardman N, Lee Gill L, Winter de RFJ, et al: Generation of a recombinant human-mouse chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer 44:424-433, 1989
25. Hollinger P, Winter G: Diabodies: Small bispecific antibody fragments. Cancer Immunol Immunother 45:128-130, 1997
26. Terskikh AV, Le Doussal JM, Crameri R, et al: "Peptibody": A new type of high avidity binding protein. Proc Natl Acad Sci U S A 94:1663-1668, 1997
27. Bischof Delaloye A, Delaloye B: Radiolabeled monoclonal antibodies in tumor imaging and therapy: Out of fashion? Eur J Med 22:571-580, 1995
28. Minna JD, Higgins GA, Glatstein EJ: Cancer of the lung, in deVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (Ed 2). Philadelphia, PA, JB Lippincott, 1985, pp 507-597
29. Larson SM, Brown JP, Wright PW: Imaging of melanoma with I-131 monoclonal antibodies. J Nucl Med 24:123-129, 1982
30. 111In-labeled monoclonal antibody imaging of primary lung carcinoma. Nucl Med Commun 7:729-739, 1986
31. 111In-labeled HMFGI F(ab′)2 fragments. Cancer Res 48:1977-1984, 1988
32. Schwartz A, Steinstrasser A: A novel approach to Tc-99m labeled monoclonal antibodies. J Nucl Med 28:721, 1987
33. Said JW, Nash G, Tepper G, et al: Keratin proteins and carcinoembryonic antigen in lung carcinoma: An immunoperoxidase study of 54 cases with ultrastructural correlations. Hum Pathol 14:70-76, 1983
34. Holden J, Churg A: Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 8:277-279, 1984
35. Krishnamurthy S, Morris JF, Antonovic R, et al: Evaluation of primary lung cancer with indium 111 anti-carcinoembryonic antigen (type ZCE-025) monoclonal antibody scintigraphy. Cancer 65:458-465, 1990
36. Biggi A, Gianfranco B, Ferrigno D, et al: Detection of suspected primary lung cancer by scintigraphy with indium-111-anticarcinoembryonic antigen monoclonal antibodies (type FO23C5). J Nucl Med 32:2046-2068, 1991
37. Bourguet P, Dazord L, Desrues B, et al: Immunoscintigraphy of human lung squamous cell carcinoma using an iodine-131 labeled monoclonal antibody (Po66). Br J Cancer 61:230-234, 1990
38. Ihde DC, Hansen HH: Staging procedures and prognostic factors in small cell carcinoma of the lung, in Greco FA, Oldham RK, Bunn PA Jr (eds): Small Cell Lung Cancer. New York, NY, Grune & Stratton, 1981, pp 261-283
39. Nelp WB, Griep RG, Salk D, at al: Staging of small cell cancer of the lung using Rc-99m labeled antibody (Fab), in Haseman MK (ed): Frontiers of Nuclear Medicine: Diagnostic Uses of Radiolabeled Monoclonal Antibodies. Washington, DC, American College of Nuclear Physicians, 1992, pp 15-20
40. Abrams P, Fer M, Faubion C, et al: A new procedure for staging small cell lung cancer (SCLC): Gamma camera imaging using a technetium-99m labeled monoclonal antibody Fab. Am Soc Clin Oncol 9:A895, 1990 (abstr)
41. Balaban EP, Walker BS, Cox JV, et al: Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody. A comparison with standard staging methods. Clin Nucl Med 17:439-445, 1992
42. Vansant JP, Johnson DH, O'Donnell DM, et al: Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clin Nucl Med 17:431-437, 1992
43. Friedman S, Sullivan K, Salk D, et al: Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. Hematol Oncol Clin North Am 4:1069-1078, 1990
44. Rusch V, Macapinlac H, Heelan R, et al: NR-LU-10 monoclonal antibody scanning: A helpful new adjunct to CT in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg 106:200-204, 1993
45. Vuillez JP, Moro D, Brichon PY, et al: Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 38:507-511, 1997
46. Reubi JC, Shaer JC, Markwalder R, et al: Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance. Yale J Biol Med 70:471-479, 1997
47. 123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993
48. 111In-DTPA octreotide scintigraphy: Preliminary results. J Cardiovasc Surg 37:653-656, 1996
49. Kirsch C-M, von Pawel J, Grau I, et al: Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 21:1318-1325, 1994
50. O'Byrne KJ, Halmos G, Pinski J, et al: Somatostatin receptor expression in lung cancer. Eur J Cancer 30A:1682-1687, 1994
51. Kwekkeboom DJ, Kho GS, Lamberts SWJ, et al: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106-1113, 1994
52. 111In-DTPA octreotide scintigraphy. Eur J Cancer 31A:184-188, 1995
53. Stokkel MPM, Pauwels EKJ: Octreotide scintigraphy for small cell lung carcinoma: Past, present or future? Eur J Nucl Med 21:1276-1278, 1994
54. Nilsson O, Kolby L, Wangberg B, et al: Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumors. Br J Cancer 77:632-637, 1998
55. Leitha T, Studnicka M, Marosi M, et al: The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 34:1397-1402, 1993
56. Maini CL, Tofani A, Venturo I, et al: Somatostatin receptor imaging in small cell lung cancer using indium-11-DTPA octreotide: A preliminary study. Nucl Med Commun 13:962-968, 1993
57. Hochstenbag MMH, Heidendal GAK, Wouters EFM, et al: In-111 octreotide imaging in staging of small cell lung cancer. Clin Nucl Med 22:811-816, 1997
58. Reisinger I, Bohuslavitzki KH, Brenner W, et al: Somatostatin receptor scintigraphy in small-cell lung cancer: Results of a multicenter study. J Nucl Med 39:224-227, 1998
59. O'Byrne KJ, Ennis JT, Freyne PJ, et al: Scintigraphic imaging of small-cell lung cancer with [indium-111] pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 69:762-766, 1994
60. Macauly VM, Smith IE, Everard MJ, et al: Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 64:451-456, 1991
61. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. J Nucl Med 41:1808-1812, 2000
62. Lonneux M, Jamar F, Leners N, et al: Uptake of In-111 pentetreotide by pleural plaques. Clin Nucl Med 23:298-301, 1998
63. Olmos RAV, vanZandwijk N, Boersma LJ, et al: Radiation pneumonitis with indium-111-pentetreotide. J Nucl Med 37:584-588, 1996
64. Vallabhajosula S, Moyer BR, Lister-James J, et al: Preclinical evaluation of technetium-99m-labeled somatostatin receptor binding peptides. J Nucl Med 37:1016-1022, 1996
65. 99mTc-P829. Cancer Res 58:1850-1859, 1998
66. Virgolini I, Pangerl T, Bischof C, et al: Somatostatin receptor expression in human tissues: A prediction for diagnosis and treatment of cancer: Eur J Clin Invest 27:645-647, 1997
67. O'Byrne K, Carney D: Somatostatin and the lung. Lung Cancer 10:151-172, 1993
68. Fujita T, Yamaji Y, Sato M, et al: Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 55:1797-1806, 1994
69. Blum JE, Handmaker H, Rinne NA: The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 115:224-232, 1999
70. 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 117:1232-1238, 2000
71. Gambhir SS, Shephard JE, Handmaker H, et al: Analysis of the cost-effectiveness of a somatostatin analog-Tc99m-depreotide (NeoTect) in the scintigraphic evaluation of solitary pulmonary nodules (SPN). J Nucl Med 40:57P, 1999 (suppl)
72. Kernstine KH, Kahn D, Menda Y, et al: A new technique for staging potentially-resectable lung cancer: Neotect SPECT Tc-99m (NeoT) compared with F-18 FDG. Proc Am Soc Clin Oncol 20:P1352, 2001
73. 123I-Tyr3] octreotide. Eur J Nucl Med 20:1089-1094, 1993
74. 111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 21:328-335, 1994
75. Banks WA, Shally AV, Barrera CM, et al: Permeability of the murine blood brain barrier to some octapeptide analogues of somatostatin. Proc Natl Acad Sci U S A 10:431-438, 1990
76. Decristoforo C, Mather SJ: Technetium-99m somatostatin analogues: Effect of labelling methods and peptide sequence. Eur J Nucl Med 26:869-876, 1999
77. 111In-DTPA-octreotide. Eur J Nucl Med 27:S87, 2000
78. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 42:1309-1315, 2001
79. Virgolini I, Path P, Novotny C, et al: Comparative somatostatin receptor scintigraphy, using In-111-DOTA-lanreotide and In-111 DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12:541-545, 2001
80. Okarvi SM: Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 28:929-938, 2001
81. 18F]Fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabelling, in vitro validation and biodistribution in mice. Nucl Med Biol 21:819-829, 1994
82. Wester HJ, Brockman J, Roesch F, et al: PET pharmacokinetics of F-18-octreotide: A comparison with Ga-67 DFO- and Y-86-DTPA octreotide. Nucl Med Biol 24:275-286, 1997
83. Virgolini I, Yang Q, Li S, et al: Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 54:690-700, 1994
84. Virgolini I, Raderer M, Kurtaran A, et al: Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116-1121, 1994
85. 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 23:685-692, 1996
86. 111In-DTPA-D-Phel-octreotide in 194 carcinoid patients: Vienna University experience, 1993-1998. J Clin Oncol 18:1331-1336, 2000
87. Virgolini I, Kurtaran A, Raderer K, at al: Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36:1732-1739, 1995
88. Reubi JC: In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med 36:1846-1853, 1995
89. Reubi JC, Schaer JC, Waser B: Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377-1386, 1997
90. Hennig IM, Laossue JA, Horisberger U, et al: Substance P receptors in human primary neoplasms. Int J Cancer 61:786-792, 1995
91. Behr TM, Gotthardt M, Barth A, et al: Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200, 2001
92. 125I-(Tyr4) bombesin by tumor cells. Prostate 25:29-38, 1994
93. Moody TW, Carney DN, Cuttiteta F, et al: High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci 37:105-113, 1985
94. Wood SM, Wood JR, Ghatei MA, et al: Bombesin somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab 53:1310-1312, 1981
95. Toi-Scott M, Jones CL, Kane MA, et al: Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer 15:341-354, 1996
96. Chaudhry A, Carrasquillo JA, Avis IL, et al: Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 5:3385-3393, 1999
97. Kelley MJ, Linnoila RI, Avis IL, et al: Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256-261, 1997
98. 111In-DTPA-Pro(2), Tyr(4)] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83:657-663, 1999
99. Baidoo KE, Lin KS, Zhan Y, et al: Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 9:218-225, 1998
100. Cuartero-Plaza A, Martinez-Miralles E, Rosell R, et al: Radiolocalization of squamous lung carcinoma with I-131-labeled epidermal growth factor. Clin Cancer Res 2:13-20, 1996
101. Lafrenie RM, Gallo S, Podor TJ, et al: The relative roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to interleukin-1-treated endothelial cells. Eur J Cancer 30A:2151-2158, 1994
102. Breitz HB, Sullivan K, Nelp WB, et al: Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med 23:127-132, 1993